Science & Enterprise subscription

Follow us on Twitter

  • A system combining a tiny sensor with oral chemotherapy drugs aims to provide physicians with closer monitoring of… https://t.co/d7zQTiPu0d
    about 12 hours ago
  • New post on Science and Enterprise: Sensor-Pill System Designed for Cancer Drugs https://t.co/8E3S6HzHnR #Science #Business
    about 12 hours ago
  • A start-up enterprise begun by students at Purdue University developed an iPhone app that detects mild brain injur… https://t.co/O2tT9TT0WO
    about 19 hours ago
  • New post on Science and Enterprise: Univ. Spin-Off Creates Concussion Detection App https://t.co/36YOIKD3b7 #Science #Business
    about 19 hours ago
  • New contributed post on Science and Enterprise: https://t.co/FRFje5nx6N Technology That Builds Bridges Between Teams
    about 23 hours ago

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn
INSTAGRAM

Collaboration to Research Obesity Biomarkers, Drug Targets

Feet on bathroom scale (Genome.gov)

(Genome.gov)

Florida Hospital in Orlando, Sanford-Burnham Medical Research Institute also in Orlando, and Takeda Pharmaceutical Company in Osaka, Japan, will collaborate on developing new therapies for obesity, a growing worldwide health problem. The partnership aims to to identify and validate new obesity-related biomarkers and molecular targets.

The project is the first corporate-sponsored research undertaken by the Translational Research Institute for Metabolism and Diabetes (TRI), a partnership of Florida Hospital and Sanford-Burnham. The two-year agreement includes research funding from Takeda divided between Florida Hospital-TRI and Sanford-Burnham.

The planned work design combines lab research with clinical investigations of patients that can help scientists compare data from experimental models and humans to identify genetic and metabolomic matches. The partners expect to use technologies such as genomic and metabolite profiling to pinpoint metabolic signatures, genes, and pathways that could serve as biomarkers. They also anticipate identifying drug targets to help develop more personalized treatments for obesity and its complications.

According to the U.S. Centers for Disease Control, over one-third of Americans are overweight and another one-third is obese. Obesity leads to numerous serious illnesses, including type 2 diabetes, high cholesterol, hypertension, gallstones, fatty liver disease, sleep apnea, heart failure, birth defects, miscarriages, asthma, and some forms of cancer.  Obesity causes at least 112,000 excess deaths in the U.S. each year and reduces lifespan by up to eight years.  Medical-related expenses attributable to obesity are projected to top $344 billion by 2018.

*     *     *

Please share Science & Enterprise ...

3 comments to Collaboration to Research Obesity Biomarkers, Drug Targets